Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
IBD
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - IBD
    Researchers Discover Mutations In Two Genes That Cause Early-Onset IBD - (DGNews)
    Isotretinoin Use Linked to Increased Risk of IBD: Presented at ACG - (DGDispatch)
    Patients With Ulcerative Colitis Who Have Worst Baseline Disease Are Most Likely to Relapse: Presented at ACG - (DGDispatch)
    TopAbstracts in IBD 10/27/2009 - (DGNews)
    Patients Previously on Steroids Maintain Remission From Ulcerative Colitis With Mesalamine Granules: Presented at ACG - (DGDispatch)

    News archive

     Recent webcasts/CME - IBD
    • Biologics in Crohn's Disease: Treating Early, Treating Long-Term
    • Advances in Medical Therapy for Crohn's Disease
      Advances in Surgical Treatments for Crohn's Disease
      Management Strategies for Complex Crohn's Disease Case Presentations
      Biologic Therapies III The New Agents

      Webcasts/CME archive

       Recent cases - IBD
        A 47-Year-Old Man with Neuro-Sweet Syndrome in Association with Crohn's Disease: A Case Report
        Tracheobronchitis in a Patient with Crohn's Disease
        Hepatocellular Carcinoma and Crohn's Disease: A Case Report and Review
        Crohn's Disease
        Pneumocystis Jiroveci Pneumonia and Pneumomediastinum in an Anti-Tnfalpha Naive Patient with Ulcerative Colitis

        Cases archive
          




        my personal edition > ibd > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Natalizumab Improves Quality of Life for Patients with Crohn's Disease: Presented at DDW

        By Ed Susman

        ORLANDO, FL -- May 23, 2003 -- Natalizumab, the investigational monoclonal antibody to alpha-4 integrin, appears to improve the quality of life in patients with active Crohn's Disease, researchers noted on May 20th here at Digestive Disease Week 2003.

        In a Phase II, randomised, double-blind study of natalizumab, doctors analysed responses of 248 patients to the Inflammatory Bowel Disease Questionnaire (IBDQ). The IBDQ is a validated psychological instrument that measures four quality-of-life domains: bowel and systemic symptoms, and emotional and social function.

        "Significant improvements in all four domains of the questionnaire were seen in patients receiving two infusions of natalizumab compared to those receiving placebo," said Dr. Stephen Donoghue, PhD, head of the European Clinical Research Group of Elan Pharmaceuticals, Stevenage, United Kingdom.

        Dr. Donoghue explained that the quality-of-life improvements were assessed six weeks after the beginning of treatment with natalizumab.

        Bowel symptoms increased from an IBDQ score of 41 to 44 points in the placebo group; from 38 to 47 points in patients on a low-dose 3 mg/kg infusion of natalizumab; from 42 to 50 points in patients receiving two 3 mg/kg infusions of natalizumab; and from 37 to 47 points in patients receiving two 6 mg/kg infusions of natalizumab (P<0.005 vs. placebo).

        Similar differences were seen for systemic symptoms (P<0.05), emotional function (P<0.005) and social function (P<0.05).

        "These results further suggest that natalizumab may hold promise for treatment of Crohn's disease," Dr. Donoghue stated.

        Digestive Disease Week 2003 is jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract.

        This study was funded by Elan Pharmaceuticals.


        [Study title: Quality of Life Improvements in a Phase 2 Study of Natalizumab for Active Crohn's Disease. Abstract 105724]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send